# US 2012/0253010 A1 · Compound accumulating in inflammatory site, diagnostic agent containing the compound in labeled state and its precursor compound for labeling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253010 A1
- Document ID: US20120253010A1
- Status: Published application
- Kind: A1
- Application number: 13/434,722
- Filed: 2012-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Assignees: Nihon Medi-Physics Co., Ltd.; Kyoto University
- Inventors: Hideo Saji; Hiroyuki Kimura; Masahiro Ono; Ikuya Seki
- Web page: https://patentgrep.com/patent/US20120253010A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Embodiments of the invention provide a compound accumulating in an inflammatory site, a diagnostic agent containing the compound in labeled state and its precursor compound for labeling. Such a compound accumulating in inflammatory site may be represented by the following formula (1): Z—Y-Leu-Phe-(X)n-DLys(-(DLys)m-HalB)-(DLys)k-NH2 (1) wherein in the formula (1), Z represents a protective group for an amino group; Y represents Met or Nle; X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds; n represents 1 or 0; m represents 1 or 0; k represents 1 or 0; and HalB represents a substituted benzoic acid having a radioactive halogen in an aromatic ring.

## Claims

### Claim 1

A compound accumulating in inflammatory site represented by a following formula (1):
Z—Y-Leu-Phe-(X)n-DLys(-(DLys)m-HalB)-(DLys)k-NH2 (1)
wherein, in the formula (1),
Z represents a protective group for an amino group;
Y represents Met or Nle;
X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds;
n represents 1 or 0;
m represents 1 or 0;
k represents 1 or 0; and
HalB represents a substituted benzoic acid having a radioactive halogen in its aromatic ring.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein Z in the formula (1) is a formyl group.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein X in the formula (1) is (-Nle-Tyr-) and n is 1.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein said radioactive halogen in HalB is 121I.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein said radioactive halogen in HalB is 123I.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein said radioactive halogen in HalB is 125I.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein said radioactive halogen in HalB is 131I.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein said radioactive halogen in HalB is 124I.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein the said radioactive halogen in HalB is 18F (HalB in this case is represented by [18F]FB).

### Claim 10 (depends on 1)

The compound according to claim 1, wherein said compound represented by the formula (1) is formyl-Met-Leu-Phe-Nle-Tyr-DLys-ε([18F]FB)-NH2.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein said compound represented by the formula (1) is formyl-Met-Leu-Phe-Nle-Tyr-DLys-DLys-ε([18F]FB)-NH2.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein said compound represented by the formula (1) is formyl-Nle-Leu-Phe-Nle-Tyr-DLys-ε([18F]FB)-NH2.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein said compound represented by the formula (1) is formyl-Nle-Leu-Phe-Nle-Tyr-DLys-DLys-ε([18F]FB)-NH2.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein said compound represented by the formula (1) is formyl-Nle-Leu-Phe-Nle-Tyr-DLys-ε([18F]FB)-DLys-NH2.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein said compound represented by the formula (1) is formyl-Met-Leu-Phe-Nle-Tyr-DLys-ε([18F]FB)-DLys-NH2.

### Claim 16 (depends on 1)

A precursor compound for radiolabeled compounds according to claim 1, represented by the formula (2):
Z—Y-Leu-Phe-(X)n-DLys-(DLys)m-(DLys)k-NH2 (2)
wherein, in the formula (2),
Z represents a protective group for an amino group;
Y represents Met or Nle;
X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds;
n represents 1 or 0;
m represents 1 or 0; and
k represents 1 or 0.

### Claim 17

A diagnostic agent for imaging an inflammatory site, comprising a radioactive compound as an active ingredient, the compound being represented by the following formula (1):
Z—Y-Leu-Phe-(X)n-DLys(-(DLys)m-HalB)-(DLys)k-NH2 (1)
wherein, in the formula (1),
Z represents a protective group for an amino group;
Y represents Met or Nle;
X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds;
n represents 1 or 0;
m represents 1 or 0;
k represents 1 or 0; and
HalB represents a substituted benzoic acid having a radioactive halogen in its aromatic ring.

### Claim 18 (depends on 17)

The compound according to claim 17, wherein Z in the formula (1) is a formyl group.

### Claim 19 (depends on 17)

The compound according to claim 17, wherein X in the formula (1) is (-Nle-Tyr-) and n is 1.

### Claim 20

A diagnostic agent for imaging an inflammatory site associated with a diabetic foot, comprising a compound being represented by the following formula (1):
Z—Y-Leu-Phe-(X)n-DLys(-(DLys)m-HalB)-(DLys)k-NH2 (1)
wherein, in the formula (1),
Z represents a protective group for an amino group;
Y represents Met or Nle;
X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds;
n represents 1 or 0;
m represents 1 or 0;
k represents 1 or 0; and
HalB represents a substituted benzoic acid having a radioactive halogen in its aromatic ring.
